Evaluation of The Possible Effect of Trimetazidine, Empagliflozin in comparison with Methotrexate in a rat model of Rheumatoid Arthritis | ||
| Benha Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 15 January 2025 PDF (1.14 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bmfj.2025.335322.2250 | ||
| Authors | ||
| Caterine Nabil Matta* 1; Nasr Nazmy Zaki Makar2; Mohie ELDin Elsayed Sherif2; Amany Nasr Ibrahim2; Abeer Attia Abd Elhameed3 | ||
| 1Assistant Lecturer of Clinical Pharmacology, Faculty of Medicine, kafr El-Sheikh University, Egypt | ||
| 2Professor of Clinical Pharmacology, Faculty of Medicine, Benha University, Benha, Egypt | ||
| 3Assistant Professor of Clinical Pharmacology, Faculty of Medicine, Benha University, Benha, Egypt | ||
| Abstract | ||
| Background: Rheumatoid arthritis (RA) is a chronic, relapsing inflammatory and autoimmune multisystem disease. The main cause of mortality in RA is cardiovascular catastrophes. Methotrexate is considered the most important Disease-Modifying Anti-Rheumatic Drug. Trimetazidine is a metabolic modulator‐antianginal agent with potent antioxidant, anti-inflammatory, and cytoprotective effects. Empagliflozin is an antidiabetic agent that selectively inhibits sodium–glucose cotransporter 2 in proximal renal tubules with anti-inflammatory and cardio- renal protective properties. Aim of the study: The present study was designed to evaluate the possible effects of methotrexate, trimetazidine and empagliflozin in a rat model of RA. Materials and methods Rats were classified into: Group I: control normal group. Group II: was not treated (diseased group). Group III: was treated with methotrexate. Group IV: was treated with trimetazidine. Group V: was treated with empagliflozin. Group VI: was treated with combination of MTX with trimetazidine. Group VII: was treated with combination of MTX with empagliflozin. Treated groups received drugs for 4 weeks. Results: Treated groups showed significant improvement in (rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), tumor necrosis factor alpha (TNF-α), interlukien-6 (IL-6), C-reactive protein (CRP), reduced glutathione (GSH), cardiac Troponin-I (CTn-I), arthritis score) and improvement of the histopathology of the joint and myocardium. A significant reduction in the score was seen in the treated groups at the end of 3rd and 4th weeks, with best results in MTX+EMPA combination group. Conclusion: All tested drugs alone or in combination showed improvement of parameters of RA with cardioprotective properties. | ||
| Keywords | ||
| Rheumatoid arthritis; Methotrexate; Trimetazidine; Empagliflozin; Cardio- protection | ||
|
Statistics Article View: 339 PDF Download: 146 |
||
